VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.41 (−14.09%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Viridian Therapeutics, Inc.\DE grew revenue 23220.3% to $71.13M over the twelve months to Jun 30, 2026. Free cash flow was -$335.04M.
Revenue
$71.13M
+23220.3% vs. a year earlier
Operating income
-$405.20M
TTM Q2 2026
Free cash flow
-$335.04M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $71.13M
- Net income
- -$386.97M
- Free cash flow
- -$335.04M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$71.13M+23220.3% YoY
Gross profit
–
Operating income
-$405.20M
Net income
-$386.97M
EPS, diluted
–
Free cash flow
-$335.04M
Reported periodTrailing twelve months